PAVmed (PAVM) AI Stock Analysis

• Market Cap: $8.62M
• Dividend Yield: N/A
• Average Volume (3M): 377.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: -99.28%
• EPS Growth: -46.16%
• Country: US
• Employees: 39
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.29
• Shares Outstanding: 29,671,925
• 10 Day Avg. Volume: 774,204
• 30 Day Avg. Volume: 377,786
• PEG Ratio: >-0.01
• Price to Book (P/B): -2.43
• Price to Sales (P/S): 2.03
• P/FCF Ratio: -0.18
• Enterprise Value/Market Cap: 4.02
• Enterprise Value/Revenue: 509.14
• Enterprise Value/Gross Profit: -70.95
• Enterprise Value/Ebitda: -3.96
• 1Y Price Target: $17.00
• Price Target Upside: 5762.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $0.50 ▲(72.41% Upside)

PAVmed's overall stock score is primarily impacted by its financial challenges, including persistent losses and negative cash flows. Technical indicators show a bearish trend, and valuation metrics are weak due to unprofitability. The earnings call provided some positive strategic updates, but ongoing challenges in revenue growth and debt restructuring remain significant concerns.

Positive Factors

Innovative Product Portfolio

PAVmed's focus on innovative medical devices positions it well to address unmet medical needs, potentially driving long-term growth and market differentiation.

Strategic Partnerships

Strategic partnerships expand PAVmed's market reach and product offerings, which can lead to increased sales and a stronger competitive position over time.

Manageable Leverage

Manageable leverage indicates that PAVmed can sustain its debt levels without significant financial strain, supporting long-term operational stability.

Negative Factors

Persistent Losses

Ongoing losses and negative cash flows highlight profitability issues, which could hinder PAVmed's ability to invest in growth and innovation.

Negative Profit Margins

Negative profit margins suggest inefficiencies in cost management, impacting PAVmed's ability to achieve sustainable profitability.

Cash Flow Challenges

Negative cash flows limit PAVmed's financial flexibility, potentially restricting its capacity to fund operations and future growth initiatives.

PAVmed Business Overview & Revenue Model

Company Description

PAVmed Inc. is a medical technology company focused on the development and commercialization of innovative medical devices and diagnostic tools. Operating primarily in the healthcare sector, PAVmed aims to improve patient outcomes through its core products, which include devices for gastroenterology, urology, and other specialty areas. The company is known for its commitment to addressing unmet medical needs with solutions that enhance clinical workflows and patient care.

How the Company Makes Money

PAVmed generates revenue through the sale of its medical devices and products, which are marketed to hospitals, clinics, and healthcare providers. The company has established key partnerships and collaborations that enhance its product offerings and market reach, contributing to its sales. Additionally, PAVmed's revenue model may include licensing agreements and potential royalties from its innovative technologies. The company also seeks to leverage reimbursements from insurance providers for its products, which can further enhance its revenue streams.

PAVmed Financial Statement Overview

Summary

PAVmed faces significant financial challenges, with persistent losses and negative cash flows. Despite positive revenue growth, profitability remains a critical issue. The balance sheet shows manageable leverage, but negative returns on equity highlight inefficiencies.

Income Statement

PAVmed's income statement reveals significant challenges, with negative profit margins across all metrics. The TTM gross profit margin is deeply negative, indicating costs far exceed revenues. The net profit margin is also substantially negative, reflecting ongoing losses. Despite a positive revenue growth rate, the company's profitability remains a concern due to high operating losses.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio for TTM, suggesting manageable leverage. However, the return on equity is negative, indicating inefficiencies in generating returns on shareholders' investments. The equity ratio is relatively stable, but the negative ROE highlights profitability issues.

Cash Flow

Cash flow analysis indicates negative operating and free cash flows, with a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. The free cash flow to net income ratio is close to 1, suggesting cash flow is aligned with net losses, but overall cash flow health is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	68.00K	3.00M	2.45M	377.00K	500.00K	0.00
Gross Profit	-488.00K	-3.04M	-3.97M	-3.24M	-85.00K	0.00
EBITDA	-8.74M	29.67M	-75.74M	-99.50M	-55.90M	-23.33M
Net Income	-4.58M	39.79M	-64.17M	-88.98M	-50.35M	-34.28M
Balance Sheet
Total Assets	38.07M	30.66M	33.12M	53.98M	86.98M	19.78M
Cash, Cash Equivalents and Short-Term Investments	3.10M	1.19M	19.64M	42.75M	79.25M	17.52M
Total Debt	9.28M	31.86M	48.73M	36.64M	0.00	14.96M
Total Liabilities	12.28M	37.69M	57.14M	43.05M	7.56M	20.25M
Stockholders Equity	35.78M	-2.50M	-53.83M	-9.68M	61.67M	1.90M
Cash Flow
Free Cash Flow	-8.96M	-33.61M	-52.28M	-72.53M	-42.06M	-21.97M
Operating Cash Flow	-8.91M	-33.55M	-52.04M	-70.98M	-40.59M	-21.91M
Investing Cash Flow	-48.00K	-16.18M	758.00K	-4.74M	-3.72M	-55.00K
Financing Cash Flow	11.84M	31.28M	31.17M	38.21M	104.31M	33.01M

PAVmed Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAVM, the sentiment is Negative. The current price of 0.29 is below the 20-day moving average (MA) of 0.33, below the 50-day MA of 0.38, and below the 200-day MA of 0.54, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.72 is Neutral, neither overbought nor oversold. The STOCH value of 22.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PAVM.

PAVmed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNON	49 Neutral	$12.11M	-0.38	-197.26%	―	-2.47%	91.23%
PAVM	48 Neutral	$8.62M	-0.52	20.03%	―	-99.28%	-46.16%
SSKN	43 Neutral	$7.54M	-0.47	-207.19%	―	-5.19%	-0.81%
CODX	42 Neutral	$15.66M	-0.26	-62.12%	―	-87.84%	29.16%
HSCS	40 Underperform	$7.44M	-0.38	-220.42%	―	-41.03%	35.71%
BMRA	38 Underperform	$6.99M	-1.71	-69.61%	―	-11.31%	47.64%

PAVmed Corporate Events

PAVmed Approves Reverse Stock Split Amendment

On December 5, 2025, PAVmed Inc. held a special meeting where stockholders approved an amendment to the company’s certificate of incorporation. This amendment allows for a reverse stock split at a ratio between 1-for-10 and 1-for-30, and a reduction in authorized common stock from 250 million to 25 million shares. The board of directors has yet to decide the specific ratio for the reverse split but plans to implement the changes soon by filing with the Delaware Secretary of State.

PAVmed Announces Q3 2025 Financial Results and Updates

On November 13, 2025, PAVmed Inc. announced a business update and financial results for the third quarter of 2025. The company highlighted significant advancements, including Veris Health’s commercial phase launch with The Ohio State University James Cancer Hospital and the relaunch of its implantable physiological monitor development. PAVmed also signed a letter of intent to license a new endoscopic imaging technology from Duke University, aiming to expand its innovation pipeline. Lucid Diagnostics reported $1.2 million in revenue from EsoGuard tests and received unanimous support for Medicare coverage, strengthening its financial position with a public stock offering. The company reported a GAAP net loss of $6.3 million for the quarter, with cash reserves increasing to $3.1 million.

PAVmed’s Lucid Diagnostics Completes Public Stock Offering

On September 11, 2025, Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., completed a public offering of 28,750,000 shares of its common stock at $1.00 per share, raising approximately $26.9 million after expenses. The proceeds from this offering are intended for working capital and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.